KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Change in Receivables (2016 - 2025)

Globus Medical (GMED) has disclosed Change in Receivables for 15 consecutive years, with $64.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 385.34% year-over-year to $64.2 million, compared with a TTM value of $52.2 million through Dec 2025, down 33.15%, and an annual FY2025 reading of $52.2 million, down 33.15% over the prior year.
  • Change in Receivables was $64.2 million for Q4 2025 at Globus Medical, up from $8.4 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $87.8 million in Q2 2024 and bottomed at -$23.7 million in Q3 2024.
  • Average Change in Receivables over 5 years is $12.8 million, with a median of $8.6 million recorded in 2023.
  • The sharpest move saw Change in Receivables skyrocketed 510.97% in 2023, then tumbled 371.47% in 2024.
  • Year by year, Change in Receivables stood at $6.0 million in 2021, then fell by 22.19% to $4.6 million in 2022, then soared by 179.15% to $13.0 million in 2023, then tumbled by 273.47% to -$22.5 million in 2024, then skyrocketed by 385.34% to $64.2 million in 2025.
  • Business Quant data shows Change in Receivables for GMED at $64.2 million in Q4 2025, $8.4 million in Q3 2025, and $2.2 million in Q2 2025.